Vaxart Drops 16.07% Despite Strong Norovirus Vaccine Data

On June 12, 2025, Vaxart's stock experienced a significant drop of 16.07% in pre-market trading, marking a notable decline in its share price.

Vaxart's second-generation norovirus vaccine has demonstrated enhanced immune responses in its Phase 1 study. The new vaccine showed a 141% increase in GI.1 norovirus antibodies and a 94% rise in GII.4 antibodies, indicating a stronger immune response compared to previous versions. This advancement is part of Vaxart's efforts to improve the efficacy and manufacturability of oral vaccines, which could have significant implications for future vaccine development.

Vaxart has completed the enrollment for its Phase 1 trial of the norovirus oral pill vaccine candidate. This milestone is crucial as it paves the way for further clinical trials and potential regulatory approvals. The positive data from the Phase 1 trial has been well-received, highlighting the potential of Vaxart's vaccine technology.

Vaxart is set to host a conference call to discuss the topline results from its Phase 1 trial. This call will provide investors and stakeholders with detailed insights into the trial's outcomes and the company's future plans. The positive Phase 1 results have generated optimism about the vaccine's potential, which could influence investor sentiment and future stock performance.